Insider Buying: RxSight, Inc. (NASDAQ:RXST) Director Purchases 1,443 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 1,443 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were purchased at an average cost of $31.18 per share, with a total value of $44,992.74. Following the purchase, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley acquired 11,111 shares of RxSight stock. The shares were purchased at an average cost of $45.37 per share, for a total transaction of $504,106.07.

RxSight Stock Down 2.5 %

Shares of NASDAQ:RXST opened at $30.39 on Friday. RxSight, Inc. has a 12 month low of $26.29 and a 12 month high of $66.54. The company has a 50-day moving average price of $38.97 and a 200-day moving average price of $46.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in shares of RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the last quarter. Quarry LP lifted its stake in RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after acquiring an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new stake in RxSight in the third quarter valued at $34,000. Quest Partners LLC purchased a new position in RxSight during the 2nd quarter valued at $41,000. Finally, Harbor Investment Advisory LLC bought a new position in RxSight in the 4th quarter worth $52,000. Institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on RXST shares. UBS Group initiated coverage on shares of RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Monday, January 13th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Stifel Nicolaus reduced their price objective on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research note on Monday, January 13th. Finally, Wells Fargo & Company lowered their target price on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $58.13.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.